S 16961
Alternative Names: S 169611Latest Information Update: 12 Jul 1999
Price :
$50 *
At a glance
- Originator Servier
- Class Antihyperlipidaemics
- Mechanism of Action Nicotinic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hyperlipidaemia
Most Recent Events
- 12 Jul 1999 No-Development-Reported for Hyperlipidaemia in France (PO)
- 20 Feb 1997 New profile
- 20 Feb 1997 Phase-I clinical trials for Hyperlipidaemia in France (PO)